U.S. Markets closed

Sage Therapeutics, Inc. (SAGE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
79.88+1.91 (+2.45%)
At close: 4:00PM EST

79.84 -0.04 (-0.05%)
After hours: 4:11PM EST

Sage Therapeutics, Inc.

215 First Street
Cambridge, MA 02142
United States
617-299-8380
http://www.sagerx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees675

Key Executives

NameTitlePayExercisedYear Born
Dr. Jeffrey M. JonasCEO, Pres & Director983.77kN/A1953
Ms. Kimi E. IguchiCFO & Treasurer536.37k2.7M1962
Mr. Michael CloonanChief Operating Officer582.75k2.54M1971
Ms. Anne Marie CookSr. VP, Gen. Counsel & Sec.564.84k2.14M1962
Dr. Stephen J. KanesChief Medical Officer580.67k973.02k1965
Dr. Heinrich Schlieker Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Dr. Albert J. RobichaudChief Scientific OfficerN/AN/A1961
Mr. Matthew CalistriVP of Investor RelationsN/AN/AN/A
Ms. Erin E. LancianiSr. VP of People & Organizational StrategyN/AN/A1969
Dr. Amy SchacterleSr. VP of Global Regulatory Affairs & PolicyN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217 in Japan, Taiwan, and South Korea. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Sage Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 10. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.